Vor Bio to sell $75 million of stock in private placement led by TCGX
On March 26, 2026, Vor Bio agreed to sell 5,338,078 common shares at $14.05 each, for gross proceeds of approximately $75.0 million, to entities affiliated with TCGX. Closing is expected March 30, 2026, and the company will have 54,185,582 shares outstanding afterward, so existing shareholders will hold a smaller percentage of the company. The company plans to use the net proceeds to advance its clinical pipeline and for general corporate purposes.
Key points
- 5,338,078 shares sold at $14.05 per share, for gross proceeds of approximately $75.0 million
- Closing expected March 30, 2026; 54,185,582 shares of common stock outstanding after closing
- Proceeds to advance clinical development of telitacicept, including Phase 3 trials in myasthenia gravis and primary Sjögren's disease, and for general corporate purposes
- Registration statement on Form S-3 to cover resales due within 30 days of closing, with liquidated damages if deadlines are missed
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 27, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.